STTK — Shattuck Labs, Inc.

Is STTK overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Shattuck Labs, Inc. (STTK) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $7.45. The rating moved from Neutral to Overbought on August 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Shattuck Labs, Inc. (STTK) is a small-cap, clinical-stage biotech whose near-term value is driven primarily by program-level milestones and financing execution. Sector dynamics — including continued demand for biologics and outsourced development/manufacturing — provide a constructive backdrop, but the company likely has limited revenue and a material dependence on capital markets and partnership activity. Short-term upside may follow positive data or strategic deals, while downside is concentrated around trial or regulatory failures and dilution risk. Market sentiment in the broader growth-biotech cohort is mildly constructive, which could support liquidity and financing conditions in the near term. Investors should prioritize monitoring cash runway, upcoming clinical/regulatory catalysts, and any partnership announcements when assessing directional prospects.

Key factors

  • Clinical-stage biotech profile with value tied to upcoming program milestones and data readouts
  • Sector tailwinds for biologics and CDMO/CRO demand that could lower partner/outsourcing friction and raise commercial upside
  • Limited or no meaningful revenue today, making capital runway and financing cadence a primary driver of near-term valuation
  • Market-wide risk-on tone for growth names may provide short-term support for share price and financing windows
  • Potential for partnership, licensing, or acquisition interest if clinical data is positive or if platform shows differentiation
  • Concentrated institutional and retail ownership typical of small-cap biotechs leading to elevated share-price volatility

Risks

  • Clinical or regulatory setbacks that materially reduce product probability of success
  • High cash burn and the need for near-term equity or non-dilutive financing, which could dilute existing shareholders
  • Intense competition in relevant therapeutic areas from larger pharma with greater resources
  • Manufacturing, scale-up, or supply-chain issues that delay commercialization timelines
  • Low daily trading liquidity amplifying price moves and making exits more difficult for larger orders
  • Limited public information or infrequent disclosures increasing uncertainty for investors

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for STTK — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.